首页> 外文期刊>Antiviral Research >Picornavirus non-structural proteins as targets for new anti-virals with broad activity.
【24h】

Picornavirus non-structural proteins as targets for new anti-virals with broad activity.

机译:微小RNA病毒非结构蛋白作为具有广泛活性的新型抗病毒药物的靶标。

获取原文
获取原文并翻译 | 示例
       

摘要

Picornaviridae is one of the largest viral families and is composed of 14 genera, six of which include human pathogens. The best known picornaviruses are enteroviruses (including polio, PV, and rhinoviruses), foot-and-mouth disease virus (FMDV), and hepatitis A virus (HAV). Although infections often are mild, certain strains may cause pandemic outbreaks accompanied with meningitis and/or paralysis. Vaccines are available for PV, HAV and FMDV. When the oral vaccines are given to immunocompromised individuals, they may be chronically infected, and remain secretors of vaccine-derived variants of virus for years. There is no effective prophylaxis available for these or other picornaviruses. So far, only the 3C protease from viruses in three genera has been fully characterized as an anti-viral target, whereas the mode of action of compounds targeting other non-structural proteins have remained largely unaddressed. Within the EU-supported FP6 project-VIZIER (Comparative Structural Genomics of Viral Enzymes Involved in Replication), the non-structural proteins were studied to identify conserved binding sites for broadly reactive anti-virals. The putative 2C helicase from echovirus-30 was shown to form ring-shaped hexamers typical for DNA-encoded SF3 helicases, and to possess ATPase activity. Hexamer formation of 2C from enterovirus 76 was in vitro shown to be dependent on the 44 N-terminal residues. Crystal structures of three enterovirus 3C proteases were solved and shown to be similar to those of other picornaviruses. A new binding site of VPg to the bottom of the thumb domain of CV-B3 3D polymerase was identified as a potential target. Broad anti-enterovirus compounds against 2C and 3A proteins were also identified, including thiazolobenzimidazoles (active against 2C) and TTP-8307 (targeting 3A). There is a need for more potent inhibitors against PV and other picornaviruses, which are potential silent reservoirs for re-emerging PV-like disease.
机译:Picornaviridae是最大的病毒科之一,由14个属组成,其中六个包括人类病原体。最著名的小核糖核酸病毒是肠病毒(包括脊髓灰质炎,PV和鼻病毒),口蹄疫病毒(FMDV)和甲型肝炎病毒(HAV)。尽管感染通常是轻度的,但某些菌株可能引起大流行病爆发,并伴有脑膜炎和/或瘫痪。疫苗可用于PV,HAV和FMDV。当将口服疫苗提供给免疫功能低下的人时,它们可能会被慢性感染,并且多年来仍是疫苗衍生病毒变种的分泌者。这些或其他小核糖核酸病毒尚无有效的预防方法。迄今为止,只有来自三个属的病毒的3C蛋白酶已被完全表征为抗病毒靶标,而靶向其他非结构蛋白的化合物的作用方式在很大程度上尚未解决。在欧盟支持的FP6项目-VIZIER(涉及复制的病毒酶的比较结构基因组学)中,对非结构蛋白进行了研究,以鉴定具有广泛反应性的抗病毒剂的保守结合位点。已显示来自回声病毒30的推定2C解旋酶形成了典型的DNA编码SF3解旋酶环状六聚体,并具有ATPase活性。从肠病毒76形成的2C六聚体在体外被证明依赖于44个N末端残基。三种肠病毒3C蛋白酶的晶体结构已解析,并显示出与其他微小RNA病毒的晶体结构相似。 VPg与CV-B3 3D聚合酶拇指结构域底部的新结合位点被确定为潜在的靶标。还鉴定了针对2C和3A蛋白的广泛抗肠道病毒化合物,包括噻唑烷咪唑类(对2C具有活性)和TTP-8307(针对3A)。需要更有效的针对PV和其他小核糖核酸病毒的抑制剂,它们是可能重新出现PV样疾病的潜在沉默库。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号